Phio Pharmaceuticals Story

PHIO -  USA Stock  

USD 2.18  0.03  1.36%

It seems Phio Pharmaceuticals may not have a good chance to recover from the latest slide as its shares fell again. Phio Pharmaceuticals Corp current daily volatility is 5.98 percent, with a beta of 0.64 and an alpha of -0.27 over DOW. As many millenniums are trying to avoid the latest volatility, we are going to outline Phio Pharmaceuticals Corp a little further to understand its historical price patterns. I will address the reasons why this entity does not get much respect from institutional investors under the current market uncertainty.
Published over a month ago
View all stories for Phio Pharmaceuticals | View All Stories
Is Phio Pharmaceuticals (NASDAQ:PHIO) a new disruptor?
The company conducts business under Healthcare sector and is part of Biotechnology industry.
The company holds a Beta of 0.6383, which implies possible diversification benefits within a given portfolio. Let's try to break down what Phio Pharmaceuticals's beta means in this case. As returns on the market increase, Phio Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding Phio Pharmaceuticals will be expected to be smaller as well. Even though it is essential to pay attention to Phio Pharmaceuticals Corp current trending patterns, it is always good to be careful when utilizing equity existing price patterns. Our philosophy towards forecasting any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Phio Pharmaceuticals Corp exposes twenty-one different technical indicators, which can help you to evaluate its performance. Phio Pharmaceuticals Corp has an expected return of -0.25%. Please be advised to check Phio Pharmaceuticals Corp downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Phio Pharmaceuticals Corp stock performance from the past will be repeated at some point in the near future.
Investing in Phio Pharmaceuticals, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Phio Pharmaceuticals along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Phio Pharmaceuticals' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Phio Pharmaceuticals in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Phio Pharmaceuticals. Your research has to be compared to or analyzed against Phio Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Phio Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Phio Pharmaceuticals Corp.

How important is Phio Pharmaceuticals's Liquidity

Phio Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Phio Pharmaceuticals Corp ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Phio Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Phio Pharmaceuticals's total debt and its cash.

How Phio Pharmaceuticals utilizes its cash?

To perform a cash flow analysis of Phio Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Phio Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Phio Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Phio Pharmaceuticals Correlation with Peers

Investors in Phio Pharmaceuticals can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Phio Pharmaceuticals Corp. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Phio Pharmaceuticals and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Phio Pharmaceuticals is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage.
Please check volatility of Phio Pharmaceuticals for more details

Purchase by Gerrit Dispersyn of 1953 shares of Phio Pharmaceuticals

Legal trades by Phio Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Phio Pharmaceuticals insider trading alert for perchase of common stock $0.0001 par value by Gerrit Dispersyn, President & CEO, on 5th of March 2021. This event was filed by Phio Pharmaceuticals Corp with SEC on 2021-03-05. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down the case for Phio Pharmaceuticals

Phio Pharmaceuticals Corp maintains Sharpe Ratio (i.e., Efficiency) of -0.0412, which implies the firm had -0.0412% of return per unit of risk over the last 3 months. Macroaxis standpoint towards forecasting the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Phio Pharmaceuticals Corp exposes twenty-one different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to check Phio Pharmaceuticals Corp risk adjusted performance of (0.009373), and Coefficient Of Variation of (3,988) to confirm the risk estimate we provide.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

A growth case for Phio Pharmaceuticals

Latest value at risk indicator falls down to -9.32. Possible price upswing?
As of the 8th of May, Phio Pharmaceuticals holds the risk adjusted performance of (0.009373), and Coefficient Of Variation of (3,988). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Phio Pharmaceuticals, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Phio Pharmaceuticals Corp, which can be compared to its competitors. Please check Phio Pharmaceuticals Corp downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Phio Pharmaceuticals Corp is priced some-what accurately, providing market reflects its current price of 2.26 per share. Please also confirm Phio Pharmaceuticals Corp total risk alpha, which is currently at (1.61) to check out the company can sustain itself at a future point.

Whereas many of the other players in the biotechnology industry are either recovering or due for a correction, Phio Pharmaceuticals may not be performing as strong as the other in terms of long-term growth potentials. With a less-than optimistic outlook for your 90 days horizon, it may be a good time to drop some or all of your Phio Pharmaceuticals holdings as it seems the potential growth was already fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Phio Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Phio Pharmaceuticals Corp. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com